Groupe d'Etude en Oncologie du Quebec

Titre	A Randomised, Open-label, Phase 3 Trial Comparing the Efficacy and Safety of OSE2101 Versus Docetaxel in HLA-A2 Positive Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) With Secondary Resistance to Immune Checkpoint Inhibitor
Protocole ID	ARTEMIA
ClinicalTrials.gov ID	NCT06472245
Type(s) de cancer	Poumon non à petites cellules
Phase	Phase III
Type étude	Clinique
Médicament	OSE2101 versus docetaxel
Institution	CISSS DU BAS-SAINT-LAURENT HOPITAL REGIONAL DE RIMOUSKI 150 av. Rouleau, Rimouski, QC, G5L 5T1
Ville	Rimouski
Investigateur(trice) principal(e)	Dre Marie-Claude Foley
Coordonnateur(trice)	Isabelle Gagnon 418-724-3000 poste 8029
Statut	Actif en recrutement
Critètes d'éligibilité	Male or female, aged ≥ 18 years Patients expressing HLA-A2 phenotype in blood by pre-screening central laboratory Patients with histologically or cytologically squamous or non-squamous documented NSCLC, metastatic stage at study entry, not eligible for definite surgery or radiation, without EGFR, ALK and ROS1 gene alterations eligible for targeted therapy; other sensitizing mutations known to be immunosensitive are eligible in case of lack of local access to targeted therapy (i.e.; KRAS G12C and BRAF mutations) after Sponsor's agreement Patients with secondary resistance to ICI; Other inclusion and exclusion criteria will apply per protocol.
Critètes d'exclusion

Groupe d'étude en oncologie du Québec